TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$483 Million

Immunomedics, Inc.

Follow-on Offering

Lead Left Bookrunner, April 2020

Immunomedics, Inc.

Immunomedics, Inc. (“Immunomedics” or the “Company”) is developing and commercializing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. The Company received U.S. FDA accelerated approval for Trodelvy (sacituzumab govitecan) on April 22, 2020 for the treatment of adult patients with metastatic triple-negative breast cancer (“mTNBC”) who have received at least two prior therapies for metastatic disease.